Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· February 12, 2026

OKX Ventures backs STBL in strategic partnership with Hamilton Lane and Securitize to launch RWA-backed stablecoin on X Layer

View original at globenewswire.com
OKX Ventures backs STBL in strategic partnership with Hamilton Lane and Securitize to launch RWA-backed stablecoin on X Layer DUBAI, United Arab Emirates and LONDON and CONSHOHOCKEN, Pa…
Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • RWA markets are entering a new phase, where tokenization must deliver real utility, not just representation. STBL provides a purpose-built architecture for RWA backed stablecoins combined with compliant yield management. Working with Hamilton Lane and OKX Ventures we are seeking to unlock deeper liquidity, yield management and efficient utility across onchain ecosystems.

    80% confidence
  • This structure shows how tokenization unlocks effective utility when it's paired with regulated issuance and programmable settlement. By embedding institutional private credit directly into onchain money flows, we're turning tokenized assets into functional building blocks: assets that can be settled, composed and used across financial applications, not just held.

    80% confidence
  • The collaboration strengthens the foundation for highly capital efficient RWA products across the network. Working with STBL and Hamilton Lane allows us to accelerate that mission and bring users a more mature RWA ecosystem.

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com